Investigational Drug Details
| Drug ID: | D331 |
| Drug Name: | Amiodarone |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01118 |
| DrugBank Description: | Amiodarone is an antiarrhythmic drug used in a variety of settings. |
| PubChem ID: | 2157 |
| CasNo: | 1951-25-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2 |
| Structure: |
|
| InChiKey: | IYIKLHRQXLHMJQ-UHFFFAOYSA-N |
| Molecular Weight: | 645.3116 |
| DrugBank Targets: | HERG human cardiac K+ channel; Beta adrenergic receptor; Voltage-dependent T-type calcium channel subunit alpha-1I; Voltage gated L-type calcium channel; NA; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; NA |
| DrugBank MoA: | The antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor. |
| DrugBank Pharmacology: | Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It also mediates effects that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects. |
| DrugBank Indication: | Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|